Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Base editing and prime editing for sickle cell disease

Award Number: R01HL156647
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 01/01/2021
PERIOD OF PERFORMANCE END DATE: 06/30/2030

Group Awards By:

View Award Description

Base editing and prime editing for sickle cell disease - PROJECT SUMMARY Despite advances in the medical care of sickle cell disease (SCD), most patients still experience poor quality of life, progressive organ damage, and premature death. Allogeneic hematopoietic stem cell (HSC) transplantation can cure SCD but is associated with immune toxicities and only 20% of patients have optimal donors. In December 2023, two new SCD therapies based on genetic modification of autologous HSCs with Cas9 or lentiviral vector were FDA-approved. While these treatments are promising, ongoing concerns include their long- term efficacy and safety, including Cas9- or lentiviral vector-associated genotoxicities and the requirement for toxic myeloablative bone marrow (BM) conditioning to facilitate engraftment of modified HSCs. This renewal application summarizes our ongoing efforts to treat SCD using two “next-generation” genome engineering tools with potentially superior safety and efficacy than the currently approved approaches and to develop reduced toxicity BM conditioning. Aim 1 employs base editing to induce the expression of red blood cell fetal hemoglobin (HbF, 22), a potent anti-sickling agent. Aim 2 utilizes prime editing to revert the mutant SCD mutation to normal, which represents the most physiological genetic intervention and has been difficult to achieve with other technologies. Compared to Cas9, base editing and prime editing install more precise, predictable genetic changes with low levels of double strand DNA breaks that can cause structural chromosomal abnormalities, cell death, or malignant transformation. During the first four years of this grant, we optimized base editor-mediated induction of HbF and prime editor correction of the SCD mutation in BM repopulating HSCs from heathy donors and SCD patients to greater levels than achieved with Cas9-based approaches, and acceptable safety profiles. Now we will perform advanced process optimization, scale-up, and more extensive safety studies to support FDA investigational new drug applications for each strategy. Developing both strategies simultaneously will allow us to compare their outcomes directly in future clinical studies and ultimately to determine the best therapeutic approach. Long-term, we aim to couple our editing approaches with reduced toxicity methods for BM conditioning. Thus, Aim 3 explores the use of anti-CD117 (Kit) monoclonal antibody ± enhancing approaches, including low-dose total body irradiation, CD47 inhibition and antibody-drug conjugates for BM conditioning in a humanized SCD mouse model. Preliminary studies indicate that the efficacy of anti-CD117-based approaches is disease-specific and influenced by HSC gene modification. Therefore, it is essential to study these approaches specifically in gene-modified SCD HSCs and the abnormal SCD BM microenvironment. Overall, our planned studies have the potential to expand and improve curative strategies for SCD, and more generally, to create new paradigms for treating other monogenic blood disorders via precise genetic manipulation of HSCs.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $765,484 )
2026	2026	ST JUDE CHILDREN'S RESEARCH HOSPITAL INC	262 DANNY THOMAS PL	MEMPHIS	TN	38105	SHELBY	USA	Blood Diseases and Resources Research	001	6	8/4/2026	NON-COMPETING CONTINUATION	$765,484
2026	2024	ST JUDE CHILDREN'S RESEARCH HOSPITAL INC	262 DANNY THOMAS PL	MEMPHIS	TN	38105	SHELBY	USA	Blood Diseases and Resources Research	000	4	3/23/2026	NON-COMPETING CONTINUATION	$0
														Subtotal = $765,484

Issue Date FY: 2025 ( Subtotal = $830,254 )
2025	2025	ST JUDE CHILDREN'S RESEARCH HOSPITAL INC	262 DANNY THOMAS PL	MEMPHIS	TN	38105	SHELBY	USA	Blood Diseases and Resources Research	001	5	9/10/2025	COMPETING CONTINUATION	$830,254
2025	2024	ST JUDE CHILDREN'S RESEARCH HOSPITAL INC	262 DANNY THOMAS PL	MEMPHIS	TN	38105	SHELBY	USA	Blood Diseases and Resources Research	000	4	9/10/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $830,254

Issue Date FY: 2024 ( Subtotal = $761,516 )
2024	2024	ST JUDE CHILDREN'S RESEARCH HOSPITAL INC	262 DANNY THOMAS PL	MEMPHIS	TN	38105	SHELBY	USA	Blood Diseases and Resources Research	003	4	6/21/2024	NON-COMPETING CONTINUATION	$62,164
2024	2024	ST JUDE CHILDREN'S RESEARCH HOSPITAL INC	262 DANNY THOMAS PL	MEMPHIS	TN	38105	SHELBY	USA	Blood Diseases and Resources Research	002	4	2/2/2024	NON-COMPETING CONTINUATION	$699,352
2024	2023	ST JUDE CHILDREN'S RESEARCH HOSPITAL INC	262 DANNY THOMAS PL	MEMPHIS	TN	38105	SHELBY	USA	Blood Diseases and Resources Research	001	3	2/2/2024	NON-COMPETING CONTINUATION	$0
2024	2022	ST JUDE CHILDREN'S RESEARCH HOSPITAL INC	262 DANNY THOMAS PL	MEMPHIS	TN	38105	SHELBY	USA	Blood Diseases and Resources Research	000	2	10/18/2023	SUPPLEMENT FOR EXPANSION	$0
														Subtotal = $761,516

Issue Date FY: 2023 ( Subtotal = $777,057 )
2023	2023	ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.	262 DANNY THOMAS PL	MEMPHIS	TN	38105	SHELBY	USA	Blood Diseases and Resources Research	000	3	2/27/2023	NON-COMPETING CONTINUATION	$777,057
														Subtotal = $777,057

Issue Date FY: 2022 ( Subtotal = $897,670 )
2022	2022	ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.	262 DANNY THOMAS PL	MEMPHIS	TN	38105	SHELBY	USA	Blood Diseases and Resources Research	002	2	8/19/2022	SUPPLEMENT FOR EXPANSION	$182,000
2022	2022	ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.	262 DANNY THOMAS PL	MEMPHIS	TN	38105	SHELBY	USA	Blood Diseases and Resources Research	001	2	6/13/2022	NON-COMPETING CONTINUATION	$71,567
2022	2022	ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.	262 DANNY THOMAS PL	MEMPHIS	TN	38105	SHELBY	USA	Blood Diseases and Resources Research	000	2	2/25/2022	NON-COMPETING CONTINUATION	$644,103
														Subtotal = $897,670

Issue Date FY: 2021 ( Subtotal = $733,558 )
2021	2021	ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.	262 DANNY THOMAS PL	MEMPHIS	TN	38105	SHELBY	USA	Blood Diseases and Resources Research	001	1	8/5/2021	NEW	$0
2021	2021	ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.	262 DANNY THOMAS PL	MEMPHIS	TN	38105	SHELBY	USA	Blood Diseases and Resources Research	000	1	12/31/2020	NEW	$733,558
														Subtotal = $733,558

Grand Total All Awards = $4,765,539

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Base editing and prime editing for sickle cell disease

Award Number: R01HL156647

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 01/01/2021

PERIOD OF PERFORMANCE END DATE: 06/30/2030

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer